Progress in the treatment of multiple myeloma

Lancet

Volumn 367, Issue 9513, 2006, Pages 791-792

  Kumar, Shaji ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BORTEZOMIB; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; LENALIDOMIDE; MELPHALAN; PREDNISONE; STEROID; THALIDOMIDE;

ANTINEOPLASTIC ACTIVITY; BIRTH DEFECT; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; COST BENEFIT ANALYSIS; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; FOLLOW UP; HUMAN; INFECTION; INTERMETHOD COMPARISON; LEUKEMIA; MYELOMA; NEUROTOXICITY; NEUTROPENIA; NOTE; ORTHOSTATIC HYPOTENSION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; RISK ASSESSMENT; SOMNOLENCE; STEM CELL TRANSPLANTATION; TERATOGENICITY; THROMBOEMBOLISM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM;

EID: 33644839668     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)68311-6     Document Type: Note

References (12)

1. DM Parkin, F Bray, J Ferlay, P Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108
2. R Alexanian, A Haut, AU Khan Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens JAMA 208 1969 1680 1685
3. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials Myeloma Trialists' Collaborative Group J Clin Oncol 16 1998 3832 3842
4. M Attal, JL Harousseau, AM Stoppa A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: Intergroupe Francais du Myelome N Engl J Med 335 1996 91 97
5. JA Child, GJ Morgan, FE Davies High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma N Engl J Med 348 2003 1875 1883
6. S Singhal, J Mehta, R Desikan Antitumor activity of thalidomide in refractory multiple myeloma N Engl J Med 341 1999 1565 1571
7. S Kumar, MA Gertz, A Dispenzieri Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma Mayo Clin Proc 78 2003 34 39
8. S Kumar, KC Anderson Drug insight: thalidomide as a treatment for multiple myeloma Nat Clin Pract Oncol 2 2005 262 270
9. SV Rajkumar, E Blood, D Vesole, R Fonseca, PR Greipp Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group J Clin Oncol 24 2006 431 436
10. R Garcia-Sanz, JR Gonzalez-Porras, JM Hernandez The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma Leukemia 18 2004 856 863
11. A Palumbo, S Bringhen, T Caravita Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial Lancet 367 2006 825 871
12. T Facon, JY Mary, C Hulin Major superiority of melphalan-prednisone (MP)+thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma Blood 106 2005 780